Literature DB >> 15764222

Testicular lymphoma--a retrospective, population-based, clinical and immunohistochemical study.

Sverker Hasselblom1, Börje Ridell, Hans Wedel, Klas Norrby, Monica Sender Baum, Tor Ekman.   

Abstract

From a population-based registry, 35 patients with histologically verified testicular lymphomas were identified: diffuse large B-cell lymphomas (DLBCL) in 33 and peripheral T-cell lymphomas in two cases. Twenty-two patients had localized disease (Pe stage I and II). Twenty-eight patients received systemic chemotherapy, 17 of whom also received intrathecal prophylaxis, and 12 out of these 17 also received radiotherapy to the contralateral testis. In the Pe stage I/II group, 7 out of 21 patients in complete remission (CR) relapsed. In 5 of them the CNS was involved (isolated CNS relapse in three). Remarkably late relapses occurred (up to 127 months). Intrathecal prophylaxis seemed to reduce the frequency of relapses involving the CNS, but the relatively short follow-up (median 45 months, range 34-88, for censored patients) prevents firm conclusions regarding efficacy. The outcome for the stage IV patients was poor, with only 1 out of 11 patients in continuous CR. Immunohistochemical analysis of the DLBCL tumours revealed that 31% had the germinal centre B-cell-like phenotype. CD44 was expressed in all the tumours of stage IV patients but in less than half of the Pe stage I/II patients. A high intratumoural microvessel density was correlated with a high degree of Ki-67 positive tumour cells and an inferior overall survival.

Entities:  

Mesh:

Year:  2004        PMID: 15764222     DOI: 10.1080/02841860410002851

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  17 in total

1.  Primary testicular lymphoma with solitary cutaneous nodule as the initial presentation.

Authors:  Varsha Dalal; Manveen Kaur; Fouzia Siraj; Avninder Singh; Anju Bansal
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

2.  [B-cell lymphoma of the testes].

Authors:  V Zugor; M Frank; F S Krause; G E Schott; T Aigner; D G Engehausen
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

3.  Efficacy of prophylactic irradiation to the contralateral testis for patients with advanced-stage primary testicular lymphoma: an analysis of outcomes at a single institution.

Authors:  Ryouji Tokiya; Eisaku Yoden; Kei Konishi; Nobuhiko Kamitani; Junichi Hiratsuka; Risa Koresawa; Tadashi Hirose; Fuminori Sano; Hirotoshi Tokunaga; Toshinori Kondo; Hideho Wada; Takashi Sugihara
Journal:  Int J Hematol       Date:  2017-06-13       Impact factor: 2.490

Review 4.  Lymphoma of the testis as primary location: tumour review.

Authors:  Georgios Koukourakis; Vassilios Kouloulias
Journal:  Clin Transl Oncol       Date:  2010-05       Impact factor: 3.405

5.  Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival.

Authors:  Kunimoto Ichikawa; Masaaki Noguchi; Michiaki Koike; Nanae Aritaka; Yasunobu Sekiguchi; Yoshitaka Sunami; Miyuki Tsutsui; Masaru Hosone; Takao Hirano; Akihiko Gotoh; Norio Komatsu
Journal:  Int J Hematol       Date:  2014-08-02       Impact factor: 2.490

6.  Primary testicular lymphoma.

Authors:  Filiz Vural; Seckin Cagirgan; Guray Saydam; Mine Hekimgil; Nur Akad Soyer; Murat Tombuloglu
Journal:  J Natl Med Assoc       Date:  2007-11       Impact factor: 1.798

7.  Malignant lymphoma of the testis: a study of 12 cases.

Authors:  Andrea G Lantz; Nicholas Power; Brian Hutton; Rekha Gupta
Journal:  Can Urol Assoc J       Date:  2009-10       Impact factor: 1.862

8.  High-dose chemotherapy with autologous stem cell transplantation following systemic chemotherapy, prophylactic intrathecal methotrexate, and radiotherapy prevents relapse and improves the outcome of advanced stage primary testicular lymphoma even with cardiac involvement.

Authors:  Shin Lee; Takahiro Yamauchi; Keiichi Kinoshita; Shin Imamura; Kenichi Kamiya
Journal:  J Clin Exp Hematop       Date:  2017-09-06

9.  Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.

Authors:  Anita Kumar; Matthew A Lunning; Zhigang Zhang; Jocelyn C Migliacci; Craig H Moskowitz; Andrew D Zelenetz
Journal:  Br J Haematol       Date:  2015-10-12       Impact factor: 6.998

10.  Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma.

Authors:  Tvrtko Hudolin; Zeljko Kastelan; Ivana Ilic; Katarina Levarda-Hudolin; Nikolina Basic-Jukic; Malte Rieken; Giulio C Spagnoli; Antonio Juretic; Chantal Mengus
Journal:  J Transl Med       Date:  2013-05-16       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.